Peptimmune

About Peptimmune

Peptimmune, Inc. was a clinical-stage biotechnology firm founded in 2002, with its origins as a spin-off from Genzyme Corp. The company was established based on technology from the laboratories of Dr. Jack Strominger at Harvard University and Dr. Hidde Ploegh of the Whitehead Institute for Biomedical Research. Positioned as a developer of peptide and peptide-copolymer therapeutics, the company focused on creating treatments for central nervous system disorders and autoimmune diseases.

The company's business model revolved around the research, development, and eventual commercialization of novel therapeutics. A significant portion of its strategy involved raising capital through multiple venture financing rounds to fund clinical trials and advance its product pipeline. Over its lifespan, Peptimmune raised a total of $90.5 million. The company’s operations were centered in Cambridge, Massachusetts, a hub for the biotech industry. Key figures in its leadership included Robert Carpenter, who served as President, Chairman, and CEO, and Thomas P. Mathers, who also held the role of President and CEO at a later stage.

Peptimmune's product pipeline included several key candidates. One of its leading programs was PI-2301, a second-generation peptide copolymer designed for the treatment of multiple sclerosis (MS). This therapeutic aimed to offer a safer and more effective alternative to existing treatments like Copaxone, with the potential for more convenient dosing schedules. Another significant focus was an immunotherapeutic for pemphigus vulgaris, a rare autoimmune skin disorder. The company's technology platform also extended to soluble MHC Class II/Ig fusion proteins, which acted as molecular decoys to deactivate disease-specific immune responses without compromising overall immune function. In 2011, after a crucial Series D funding round did not materialize, Peptimmune filed for Chapter 7 bankruptcy, leading to the liquidation of its assets.